BUZZ-BioLife Solutions climbs on $1.5 billion Repligen buyout

BioLife Solutions, Inc.
Repligen Corporation

BioLife Solutions, Inc.

BLFS

0.00

Repligen Corporation

RGEN

0.00

** Shares of cell and gene therapy tools maker BioLife Solutions BLFS.O rise 2.7% to $29.99 premarket

** Life sciences company Repligen RGEN.O says it will buy BioLife in a deal valued at about $1.5 billion

** RGEN says the deal value comprises of 64% in Repligen common stock and 36% in cash

** BioLife stockholders will receive $11.25 per share in cash and 0.1442 shares of Repligen common stock, which equates to a total value of $31.00 per share — a premium of about 6.2% to BioLife's last close

** The deal is expected to close in the fourth quarter of 2026

** Up to last close, stock up 20.7% YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.